Developmental Milestones
01
First Generation (1950s–1980s)
Focused on pure titanium and Ti-6Al-4V (α+β alloy), balancing strength and machinability. However, concerns over Al/V toxicity limited their long-term medical use.
02
Second Generation (1980s–2000s)
Introduced α+β alloys like Ti-5Al-2.5Fe and Ti-6Al-7Nb, prioritizing reduced toxic elements and enhanced biocompatibility.
03
Third Generation (2000s–present)
Dominated by β-type alloys (e.g., Ti-13Nb-13Zr, Ti-24Nb-4Zr-7.6Sn), emphasizing lower elastic modulus, superior corrosion resistance, and optimized biological integration.
Corrosion Resistance Mechanisms
Medical titanium alloys rely on a self-repairing passivation layer (primarily TiO₂) formed in oxygen-rich environments. This nanoscale oxide film minimizes ion release and resists degradation in physiological fluids, ensuring long-term stability. However, localized corrosion (e.g., pitting, stress corrosion cracking) may occur under dynamic mechanical loads or in chloride-rich biofluids, necessitating material and design refinements.
Stress Corrosion Challenges
Stress corrosion cracking (SCC) in implants arises from the synergistic effects of tensile stress, corrosive media (e.g., body fluids), and microstructural defects. Key risk factors include residual stress from machining, elevated Cl⁻ concentrations, and pH fluctuations at localized corrosion sites. Advanced β-type alloys mitigate SCC through optimized phase stability (e.g., Nb/Zr additions) and reduced grain boundary reactivity.
Future Directions
Surface modification techniques (e.g., anodization) and alloy innovation remain pivotal for enhancing corrosion performance. Emerging trends prioritize low-modulus β alloys to match bone mechanics and additive manufacturing for patient-specific implants. Continuous evaluation of ion release profiles and in vivo degradation behavior will further ensure clinical safety.
